ibalizumab

ibalizumab HIV

Ibalizumab: First Long Acting HIV Treatment Available Now Via Expanded Access

No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control their viral replication. Although …

Ibalizumab: First Long Acting HIV Treatment Available Now Via Expanded Access Read More »

Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients

Shares of TaiMed Biologics Inc, which manufactures drugs to treat AIDS, soared 12.93 percent yesterday after its new TMB-355 drug for intravenous injection was granted orphan drug status in the US. The company’s shares closed at NT$151.2 yesterday, outperforming the over-the-counter benchmark index, which ended up 0.56 percent. The granting of orphan status could shorten …

Ibalizumab: First HIV Drug to Get Orphan Drug Status for Salvage Patients Read More »

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation)

All of the presentations in this section were great. The one on new drugs is contained in the last set of slides (blue slides at 1:22:46) http://webcasts.retroconference.org/console/player/19437?mediaType=podiumVideo For individual reports on each drug (Thanks to Natap.org): NEW HIV DRUGS at CROI Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals – (03/16/13) Dolutegravir (DTG) …

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation) Read More »

Fw: Hot Topics at The Body’s “Ask the Experts” Forums

From: “News at The Body” <update@news.thebody.com> Date: 06 Mar 2012 15:17:15 -0500 To: <nelsonvergel@yahoo.com> ReplyTo: “News at The Body” <update@news.thebody.com> Subject: Hot Topics at The Body’s “Ask the Experts” Forums If you have trouble reading this e-mail, you can see the online version at: www.thebody.com/topics.html March 6, 2012 Visit the Forums “Hot Topics” Library Change/Update …

Fw: Hot Topics at The Body’s “Ask the Experts” Forums Read More »

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse

The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for …

ViiV Announces Expanded Access of New Integrase Inhibitor…But Activists Are Concerned About Its Potential Misuse Read More »

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program

FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel (NelsonVergel@yahoo.com) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing  expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with …

Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program Read More »

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options

By Nelson Vergel, B.S.Ch.E., M.B.A. July 6, 2011 In a previous blog post, I reviewed the current situation for the minority of patients with HIV who have run out of treatment options. Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next …

For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options Read More »

Scroll to Top